CrushSCI.com
179.6平均天数
162中位天数
49最短天数
344最长天数
4632025发文量

Paper Review Records

全部论文审稿周期

17 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

149 天

Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin–elesclomol combination therapy

作者
Tianyu Zhu; Yongyun Li; Jieling Tang; Huimin Lin; Xiang Gu; Shengfang Ge; Lin Ye; Pengsen Wu; Xianqun Fan; Ai Zhuang; Peiwei Chai; Renbing Jia展开收起
作者单位
State Key Laboratory of Eye Health, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China; Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China; Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University, Shenzhen 518040, China展开收起
PDF源文件 DOI 网页
84 天

CMTM6 maintains B cell-intrinsic membrane CD40 stability to regulate anti-tumor immunity

作者
Runqiu Chen; Wenlong Chang; Fanglin Li; Longhua Gu; Chen Chen; Rong Zhang; Zhiying Li; Jianhua Sun; Jing Chen; Likun Gong; Yiru Long展开收起
作者单位
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Microbiological and Biochemical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201300, China; School of Public Health, China Medical University, Shenyang 110122, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China展开收起
PDF源文件 DOI 网页
230 天

H2AC19 promotes lung adenocarcinoma progression via p300/EGR1/MMP-1-mediated angiogenesis

作者
Fuwen Zuo; Jinlong Yu; Tong Liu; Xiaorui Liu; Jilong Yin; Pengzhong Ding; Yuhan Pang; Zhengdong Luo; Xiaofeng Wang; Ling Guo; Yirong Zhang; Shuang Qi; Lutao Du; Ziying Wang; Fan Yi; Xiaoshi Zhang展开收起
作者单位
Department of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China; Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China; Department of Clinical Pharmacology, The Second Hospital of Shandong University, Jinan 250033, China; Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China; School of Chinese Language and Literature, Shandong Normal University, Jinan 250014, China; Shandong Center for Food and Drug Evaruation and Inspection, Jinan 250014, China展开收起
PDF源文件 DOI 网页
344 天

A novel small molecule inhibitor targeting KHSRP methylation suppresses colon cancer progression

作者
Shuang Chen; Ningjing Zhang; Yuxiao Zhang; Jiebin Fang; Zhen Tang; Dashan Zhang; Xinyi Tang; Yalin Yu; Mengde Xia; Yan Yi; Wanjing Ding; Zhongjun Ma展开收起
作者单位
Hainan Institute, Zhejiang University, Sanya 572025, China; Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China; School of Life Sciences, Westlake University, Hangzhou 310000, China; Center of Synthetic Biology and Integrated Bioengineering, Westlake University, Hangzhou 310000, China展开收起
PDF源文件 DOI 网页
180 天

Targeting SIRT6 epigenetically restrains neutrophil hyperplasia and enhances chemotherapeutic efficacy

作者
Luping Wang; Xiaoqian Wu; Panxia Wang; Minshan Zhang; Li Li; Zhenhan Huang; Yang Mao; Haoming Chen; Qin Wen; Wei Liu; Zhibin Huang; Feifei Li; Juan Shen展开收起
作者单位
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China; The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou 510006, China; School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China; Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China展开收起
PDF源文件 DOI 网页
231 天

Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy

作者
Hong Toan Lai; Daniela Dias-Pedroso; Maria Eugénia Marques Da Costa; Romain Fernandes; Tran Ngoc Anh Nguyen; Olivia Bawa; Pierre Khneisser; João Gabriel Silva; Yassine Khalij; Michelangelo Campanella; John Griffith Jones; Svetlana Dokudovskaya; Guido Kroemer; Antonin Marchais; Nathalie Gaspar; Birgit Geoerger; Oumar Diane; Liuba Mazzanti; Tâp Ha Duong; Guy Lewin; Laurent Ferrié; Bruno Figadère; Catherine Brenner展开收起
作者单位
CNRS, Institut Gustave Roussy, Biologie du cancer et métabolisme, Université Paris-Saclay, Villejuif 94805, France; INSERM UMR 1015, Gustave Roussy Cancer Campus, Villejuif 94805, France; INSERM US23, CNRS UAR 3655, AMMICa, Experimental and Translational Pathology Platform, Gustave Roussy, Villejuif 94805, France; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France; Université Paris-Saclay, Institut Gustave Roussy, Inserm, Immunologie anti-tumorale et immunothérapie des cancers, Villejuif 94805, France; Centre for Innovative Biomedicine and Biotechnology, and III-UC-Institute of Interdisciplinary Research, University of Coimbra, Coimbra 3004-504, Portugal; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris 75006, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif 94805, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris 75015, France; Department of Oncology for child and adolescent, Gustave Roussy, Villejuif 94805, France; BioCIS, CNRS, Université Paris-Saclay, Orsay 91400, France展开收起
PDF源文件 DOI 网页

FAQ

Acta Pharmaceutica Sinica B审稿要多久?

截至2026-11-19,CrushSCI 收录了 Acta Pharmaceutica Sinica B 的 17 篇完整审稿记录。最快一篇从收稿到录用用了 49 天(Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota andl-serine metabolic pathway,2025-10-09 收稿,2025-11-27 录用),最慢一篇用了 344 天;平均 179.6 天,中位数 162 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。